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Cellular defects in the peripheral blood mononuclearGene M. Shearer*
cells (PBMC) of asymptomatic HIV-infected (HIV1) indi-Experimental Immunology Branch
viduals and AIDS patients can be demonstrated in CTL,National Cancer Institute
Th, and APC. Deficiencies of in vitro CTL responses ofNational Institutes of Health
AIDS patients can be corrected by addition of interleukinBethesda, Maryland 20892±1360
2 (IL-2) to the cultures (Rook et al., 1983), indicating that
the primary immunologic defect resides upstream of
CD81 T effector (Te) function. CD4 Th function is im-From the time of the discovery of the acquired immune
paired in asymptomatic HIV1 individuals (reviewed indeficiency syndrome (AIDS) in 1981, it was realized that
Shearer and Clerici, 1996a). In fact, loss of in vitro Ththe condition involved a critical loss of immune compe-
function as well as loss of in vivo DTH responses aretence that was reflected in susceptibility to opportunistic
key elements in the progression of HIV disease, becauseinfections previously seen primarily among immune-
both are predictive of disease progression and time tocompromised patients. Laboratory immunologic param-
death (Miedema et al., 1994; Dolan et al., 1995). Thiseters that describe this severely impaired immune sys-
conclusion is supported by the recent demonstration oftem include reduced T cell proliferative responses to
an inverse relation between HIV-specific Th activity andsoluble antigens and mitogens as well as impaired de-
HIV viremia (Rosenberg et al., 1997). Abnormalities inlayed type hypersensitivity reactions. The hallmark of
Th integrity span a range of parameters that includethis condition, recognized in the first patients, was the
reduced IL-2 receptor expression (Prince et al., 1984),depletion of CD41 T cells (reviewed in Gottlieb et al.,
preferential loss of the naive T cell subset (Roederer et1983). Within three years of the first reported AIDS
al., 1995), disturbance of the T cell Vb repertoire (Imberticases, human immunodeficiency virus type-1 (HIV) had
et al., 1991), and reduced expression of signal transduc-been isolated and identified (reviewed in Levy, 1993).
tion and activators of transcription or STATs (Pericle etThe logical interpretation of the immunologic conse-
al., 1998). Although much attention is focused on thequences of AIDS is that HIV infects and kills CD41 T
CD41 Th, helper cell abnormalities may be secondarycells, resulting in the depletion of the CD41 T cell subset.
to aberrant signaling by HIV-infected APC (Meyaard etAlthough infection with HIV is responsible for AIDS de-
al., 1993).velopment, it is important to know to what extent the
It is clear that cytokines participate in the immunepathogenesis is the result of immune-mediated mecha-
dysregulation of the syndrome. In vitro stimulation ofnisms, in contrast to a direct killing of CD41 T cells by
blood leukocytes from HIV-infected (HIV1) patientsinfection. It is clear that there is an initial strong immune
results in decreased production of IL-2, interferon-gresponse to HIV similar to and possibly stronger than
(IFNg), and IL-12 but increased production of IL-4 andthat against other viral infections. Although HIV is cyto-
IL-10 (reviewed in Shearer and Clerici, 1996a). Consis-pathic to in vitro infected CD41 T cells (reviewed in Levy
tent with the murine (Mosmann and Coffman, 1989) and1993), it can be questioned whether the percentage of
human (Romagnani, 1991) Th1/Th2 models of cytokine-infected T cells detected at any point in time can account
mediated immune regulation, the suggestion was madefor the extensive CD4 depletion observed in AIDS pa-
that HIV-induced immune dysregulation involves a Th1-tients. The loss of helper cell (Th) function is observed
to-Th2 cytokine shift (Clerici and Shearer, 1993). It isrelatively soon after infection, even before CD41 T cell
now known that HIV infection results in methylation ofdecline. In addition, both immune activation (Ascher and
the IFNg promoter, resulting in downregulation of IFNgSheppard, 1988) and loss of immune function are seen
production (Mikovits et al., 1998). The nomenclature wassimultaneously. These two observations suggest that
changed to type 1 and type 2 cytokines because immu-part of the T cell functional loss occurs independently
noregulatory cytokines other than IFNg and IL-4 (theof both direct HIV infection of CD41 T cells and of CD4
benchmark Th1 and Th2 cytokines) have been discov-numbers. This in turn suggests immune dysregulation
ered, and because AIDS patients are more complex thanrather than exclusively immune deficiency (reviewed in
clones of CD41 T cells (Clerici and Shearer, 1994). TypeShearer and Clerici, 1996a).
1 cytokines predominantly upregulate cellular (Th1-like)
responses and include IFNg, IL-2, IL-12, IL-15, and IL-
Immune Abnormalities 18. Type 2 cytokines mainly (but not exclusively) en-
Numerous abnormalities in the cells that comprise the hance (Th2-like) B cell responses such as allergy and
immune system have been identified in the developing hypereosinophilia and include IL-4, IL-5, IL-6, IL-10, and
syndrome, including polyclonal B cell activation and the IL-13 (Clerici and Shearer, 1994). The type 1/type 2 con-
production of autoantibodies, decreased cytolytic activ- cept is based on immune function rather than on two
ity of natural killer (NK) and antigen-specific cytolytic T cytokines produced by CD41 T cell clones that define
lymphocytes (CTL), reduced Th function to multiple T the Th1/Th2 model.
cell stimuli, impaired or aberrant antigen-presenting cell
(APC) activity, and disruption of immunoregulatory cyto- Pathogenesis
kine expression and production (reviewed in Levy, 1998). The pathogenesis of HIV/AIDS can be divided into two
broad categories: a direct infectious cytopathic effect
of HIV infection of CD41 T cells (viral pathogenesis)* E-mail: Gene_Shearer@nih.gov.
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Figure 1. Model of Direct and Indirect Effects
of HIV on CD41 T Cells
Direct or viral pathogenesis is shown as the
death of CD41 T cells by viral cytopathicity,
which is the consequence of HIV infection of
CD41 T cells (left side). The infection can oc-
cur by infecting CD41 T cells directly or via
intermediate infection of APC that subse-
quently infects the CD41 T cells. Indirect or
immunopathogenesis involves infection of
APC that leads to modification of expression
of a number of APC molecules (right side).
This effect includes downregulation of IL-12,
MHC class II, and CD80/86 (B7) and upregula-
tion of IL-10 and Fas, as well as expression
of FasL. Interaction between these altered
APC and the CD41 T cells involves APC-Th
signaling that results in ATCD. These modi-
fied HIV1 APC may be able to infect CD41 T
cells and could also be involved in the direct
pathogenesis pathway. It is possible that the
modification of APC could occur without
them necessarily being infected by HIV. Viral
proteins such as Tat, Nef, or gp120 might
induce some or all of the changes in APC
shown.
and indirect effects, in which immunopathogenesis is a The mechanism(s) responsible for T cell activation in
HIV1 patients remains to be elucidated. One suggestionmajor driving force (Figure 1) (reviewed in Levy, 1993;
Pantaleo and Fauci, 1995). Direct viral pathogenesis can is that some HIV peptides have superantigen-like prop-
erties (reviewed in Westby et al., 1996). Alternatively,occur by infection of the CD41 T cells themselves or via
an infected APC intermediate that passes the virus on HIV particles carry HLA-DR molecules, and these DR-
bearing virions can interact with bacterial superantigensto the T cells. Infection of CD41 T cells can also occur
via follicular dendritic cells that bind infectious HIV/anti- to activate T cells (Rossio et al., 1995). It is also possible
that HIV proteins such as Tat, Nef, gp120, or gp120±anti-HIV complexes (Heath et al., 1995).
Suggested immunopathogenic models include (1) gp120 complexes, previously shown to induce immune
suppression or cytokine dysregulation (reviewed inHIV-specific CD81 CTL that can kill HIV-infected CD41
cells (Zinkernagel and Hengartner, 1994); (2) autoim- Levy, 1998), activate T cells. These signals could prime
the T cells for ATCD in HIV1 patients.mune reactions, including autoantibodies that destroy
the immune system (reviewed in Pantaleo and Fauci, Increased T cell apoptosis is observed in unstimulated
cultures of PBMC from HIV1 patients and is further in-1995); (3) immune suppression induced by HIV proteins
such as gp120, Tat, or Nef (reviewed in Levy, 1998); (4) creased by stimulation via the T cell receptor (TCR) with
anti-CD3 or with specific antigens (reviewed in Finkelactivation of APC and/or T cells, a characteristic of HIV
disease (Fuchs et al., 1988; Ho et al., 1993); and (5) and Banda, 1994; Oyaizu and Pahwa, 1995). Stimulation
through the TCR with pan±T cell activators inducesapoptotic T cell death (ATCD), suggested to contribute
to the pathology of HIV disease (Ameisen and Capron, death of both the CD41 and CD81 subsets in PBMC
from infected patients. However, HIV-induced ATCD is1991; and reviewed in Finkel and Banda, 1994; Oyaizu
and Pahwa, 1995). That activation of APC occurs in AIDS more selective for the CD41 subset when T cell activa-
tion is induced by recall antigens or through monocytes/is supported by increased neopterin and IFNg levels in
patients' sera (reviewed in Fuchs et al., 1988) as well as macrophages (Clerici et al., 1996b; Badley et al., 1997).
Thus, the involvement of APC in HIV-induced ATCD mayincreased expression of CD40 on monocytes in HIV1
patients (Chougnet et al, 1998). Furthermore, T cells, be more selective for the CD41 Th subset than is panac-
tivation via the TCR. Characteristics of HIV-associatedparticularly the CD81 subset, exhibit increased HLA-DR
and CD38 expression (Ho et al., 1993), also reflecting T ATCD that suggest its contribution to the immunopatho-
genesis in HIV disease include the following: (1) type 1cell activation. Elevated levels of CD381CD81 T cells
are associated with reduced CD41 T cell counts (Giorgi but not type 2 cytokines protect against ATCD; (2) ATCD
is seen mainly in uninfected rather than infected T cells;et al., 1993), suggesting a connection between activa-
tion and disease progression. (3) gp120±anti-gp120 complexes can induce ATCD; (4)
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Figure 2. APC-Induced Preferential Death of Th1 Cells by ATCD and of Th2 Cells by HIV Infection
ATCD correlates with viral burden and inversely corre- aberrant T cell signaling and increased T cell apoptosis.
Such an APC is shown in the indirect immunopathogeniclates with CD4 T cell levels; (5) increased expression of
the Fas and FasL in HIV1 patients is associated with pathway in Figure 1. This modified APC might also be
capable of contributing to the direct viral pathogenesisincreased apoptotic death; (6) serum levels of lympho-
toxin (TNFb) and Fas are predictive for progression to by infection as shown. The increased expression of FasL
in lymphoid tissue of HIV1 patients appears not to beAIDS; and (7) ATCD is not a characteristic of HIV-infected
chimpanzees, a species that can be infected with HIV decreased after highly active antiretroviral therapy
(HAART) (Badley et al., 1998). This observation raisesbut rarely develops AIDS symptoms (reviewed in Clerici
et al., 1997). the possibility that antiviral therapy will be ineffective in
reversing this APC abnormality and will have little or noIn vitro infection of monocytes/macrophages results
in loss of accessory or APC function for stimulating T long-term beneficial effect on APC-induced immunopa-
thogenesis.cell responses (Ennen et al., 1990; Yoo et al., 1996) as
well as in reduced expression of MHC class II (Polyak Th1 and Th2 cells may be differentially susceptible
to HIV-induced pathogenesis by different mechanismset al., 1997) and decreased IL-12 and increased IL-10
expression/production (Chougnet et al., 1996). Mono- (Clerici and Shearer, 1994). Th1 cells are reported to be
more susceptible to apoptosis than Th2 cells (Ramsdellcytes from HIV1 patients exhibit decreased expression
of MHC class II (Clerici et al., 1991; Zwilling et al., 1991) et al., 1994; Varadhachary et al., 1997), whereas Th2
cells appear to be more susceptible to HIV infectionas well as of the B7 costimulatory molecules CD80/
86 (Dudhane et al., 1996a) and IL-12, but they exhibit (Maggi et al., 1994; Vyakarnam et al., 1995). These obser-
vations suggest that the two subsets of CD41 Th areincreased expression of IL-10 (Chougnet et al., 1996).
Thus, it is likely that the decreased expression of class differentially susceptible to death by the direct and indi-
rect mechanisms of HIV pathogenesis (Figure 2). TheII, CD80/86, and IL-12 and increased expression of IL-
10 contribute to HIV-induced immune dysregulation proportional representation of Th1-like and Th2-like
function might change, depending on the balance of thethrough aberrant T cell signaling. Monocyte/macrophages
that express reduced levels of MHC class II and CD80/ direct and indirect pathogenic mechanisms of T cell
death. This model raises the possibility that a cytokine86 can destroy CD41 Th by antibody-dependent cellular
cytotoxicity and may contribute to CD41 T cell depletion shift favoring one Th subset may be due less to expan-
sion of that subset than to accelerated death of thein HIV disease by a gp120/anti-gp120 antigen/antibody
complex±mediated mechanism (Dudhane et al., 1996b). opposing subset.
Increased expression of Fas and the de novo appear-
ance of FasL are also observed upon HIV infection of An Immune Response Failed
One of the more surprising and impressive aspects ofmonocytic cells (Badley et al., 1996), and FasL expres-
sion is upregulated in HIV-infected differentiated mac- the immunologic activity associated with HIV disease is
the speed and strength with which HIV-specific cellularrophages (Dockrell et al., 1998). These observations
indicate that the HIV-modified APC has an increased responses develop during acute HIV infection. Within
days of documented introduction of the virus, T cells inpotential for Fas- and FasL-mediated apoptotic death.
ATCD in HIV infection is dependent on monocytes/mac- the PBMC of acutely infected individuals can generate
potent CD4-mediated Th activity and CD8-mediatedrophages (Badley et al., 1997) and involves a two-step
mechanism that is gp120 dependent (Cottrez et al., CTL to HIV antigens (Koup et al., 1994; Rosenberg et
al., 1997). The CTL activity peak is coincident with the1997). Thus, APC exhibiting a combination of the charac-
teristics noted above would likely be efficient inducers of dramatic (frequently 103 to 104) drop in plasma virus
Immunity
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Figure 3. Model Illustrating HIV-Infected
APC Inducing Selective Depletion of HIV-
Specific CD41 Th by Aberrant Signaling and
ATCD
HIV-infected APC exhibit decreased expres-
sion of IL-12, class II, and CD80/86 (B7) but
increased expression of Fas, FasL, and IL-
10. The reduced levels of class II and CD80/
86 results in aberrant HIV antigen presenta-
tion to HIV-specific CD41 Th. This combina-
tion of aberrant antigen presentation and in-
creased Fas and FasL results in Th clonal
deletion via apoptotic T cell death. CD41 Th
clones specific for other antigens could be
sequentially depleted over an extended pe-
riod of time by a similar APC-induced mecha-
nism, as the patient becomes infected with
other pathogens and exposed to a spectrum
of antigens.
titers, both of which occur weeks before the appearance 3. It is also known that HIV-associated ATCD can occur
as a ªbystanderº phenomenon, killing uninfected T cellsof neutralizing serum antibodies (Koup et al., 1994; Pan-
taleo and Fauci, 1995). This kinetic pattern suggests (Finkel et al., 1995), and that monocytes/macrophages
from infected patients can induce the death of unin-that cellular immunity plays an important role in control-
ling the virus once infection has occurred. fected, activated T cells (Clerici et al., 1996b; Badley et
al., 1997; Herbein et al., 1998). This effect might also beA question that is often asked is if HIV-specific cellular
responses appear so rapidly and contribute to the dra- mediated by modified APC inducing ATCD of activated T
cells without the requirement for presentation of specificmatic reduction in plasma viremia, why does the immune
system ultimately fail to control the infection? Several antigens.
nonmutually exclusive possibilities have been sug-
gested, including (1) retention of infectious virus parti-
cles sufficient to maintain a low level of infection, despite Learning from Nature
With the current world-wide rate of HIV infection esti-the dramatic decline in plasma viremia; (2) sequestration
of HIV from immune surveillance; (3) a decline in the HIV- mated to be 16,000 per day and more than 30 million
individuals currently infected, two priorities of AIDS im-specific cellular response due to reduced HIV antigen
expression that parallels the drop in plasma virus titer; munology are to determine the optimal conditions for
generating an effective AIDS vaccine and establish pro-(4) selective activation of HIV-specific T cells that are
rendered more susceptible to HIV infection and viral tocols of immune-based therapy. The objective of a pro-
phylactic vaccine is to prevent HIV infection. The goalpathogenesis; and (5) integration of HIV proviral DNA
into infected host CD41 cells that reappears as infec- of immune-based therapy is to enhance and/or redirect
the immune systems of HIV1 individuals in whom suc-tious virus after HIV-specific T cell immune function
wanes or has been compromised (reviewed in Levy, cessful viral infection has been established. Although
these two priorities are sometimes discussed together,1998). Another possibility is the appearance of viral mu-
tations that are not recognized by protective HIV-spe- the optimal strategies to attain these goals may differ
appreciably. Immunization intended to redirect the immunecific CTL (reviewed in McMichael and Phillips, 1997).
The HIV-specific Th response appears to be the first system while simultaneously interfering with immune
activation and immunopathogenesis will likely require aT cell response to be lost after HIV infection (Clerici et
al., 1989; Miedema et al., 1994; Rosenberg et al., 1997). different strategy than immunization of an uninfected
population.This event could be initiated by HIV-infected APC that
exhibit the altered APC phenotype and present HIV anti- AIDS researchers are seeking correlates of immune
protection in both HIV1 and uninfected individuals togens to virus-specific CD41 Th (Figure 3). It is suggested
that the signals transmitted from these modified APC determine whether protective immunity can be devel-
oped against HIV. Analyses of the immune responsesto the HIV-specific Th clones, via reduced class II and/
or CD80/86 expression as well as increased Fas and of individuals who appear to have prevented or con-
trolled the infection might yield information that wouldFasL expression, should result in their selective ATCD.
This HIV-specific deletion of CD41 Th cells could occur be important for designing AIDS vaccines and devel-
oping immune-based therapy. These studies have con-soon after HIV infection and before an appreciable pro-
portion of T cells of other specificities become activated centrated on the immunologic profiles of three catego-
ries of individuals: (1) patients whose immune systemsfor ATCD. The effect would be an initial selective crip-
pling of Th immunity to HIV antigens. After the early appear to reduce the virus titer during the acute phase
of infection (Koup et al., 1994; Rosenberg et al., 1997),depletion of HIV-specific Th, repeated exposure to a
spectrum of different antigens could gradually deplete (2) long-term nonprogressors who are HIV1 but remain
without symptoms for more than 10 years (reviewedCD41 Th of these specificities over an extended period
of time, similar to the mechanism shown for HIV in Figure in Clerici et al., 1996a; Levy, 1998), and (3) exposed
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Chougnet, C., Clerici, M., and Shearer, G.M. (1996). Role of IL-12 in
systemic cellular immunity, including T helper, T effector HIV disease/AIDS. Res. Immunol. 147, 615±622.
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HIV infection and AIDS progression without inducing S., Scheer, S., and Shearer, G.M. (1998). CD40 ligand and IFN-g
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J. Immunol. 28, 646±656.
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